- AbbVie's (ABBV +0.4%) spat with Europe's drug regulator ends with the agency's acceptance of redacted documents pertaining to the company's rheumatoid arthritis drug.
- Last year, the firm sought an injunction to block the medicines regulator from releasing confidential and commercially-sensitive information about the drug.
- Researchers want access to the raw data as a means to improve third-party scrutiny of new drugs. Unsurprisingly, companies oppose this citing potential damage to their businesses and increased difficulty defending patents.